Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures.
Bolin, D.R., Swain, A.L., Sarabu, R., Berthel, S.J., Gillespie, P., Huby, N.J., Makofske, R., Orzechowski, L., Perrotta, A., Toth, K., Cooper, J.P., Jiang, N., Falcioni, F., Campbell, R., Cox, D., Gaizband, D., Belunis, C.J., Vidovic, D., Ito, K., Crowther, R., Kammlott, U., Zhang, X., Palermo, R., Weber, D., Guenot, J., Nagy, Z., Olson, G.L.(2000) J Med Chem 43: 2135-2148
- PubMed: 10841792 
- DOI: https://doi.org/10.1021/jm000034h
- Primary Citation of Related Structures:  
1D5M, 1D5X, 1D5Z, 1D6E - PubMed Abstract: 
Molecular features of ligand binding to MHC class II HLA-DR molecules have been elucidated through a combination of peptide structure-activity studies and structure-based drug design, resulting in analogues with nanomolar affinity in binding assays. Stabilization of lead compounds against cathepsin B cleavage by N-methylation of noncritical backbone NH groups or by dipeptide mimetic substitutions has generated analogues that compete effectively against protein antigens in cellular assays, resulting in inhibition of T-cell proliferation ...